Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 12/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6470652 | 0.86 | SLC6A3 (0.41) | KMT2AKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL6472499 | 0.79 | HSD11B1 (0.32) | HSD11B1 | |
| SCHEMBL29155747 | 0.73 | KMT2A (0.46) | KMT2AKDM4EALDH1A1HSD17B10HSD11B1 | |
| SCHEMBL19668539 | 0.71 | SMN1; SMN2 (0.31) | — | |
| SCHEMBL5533336 | 0.71 | HCRTR1 (0.31) | — | |
| SCHEMBL6472296 | 0.69 | HSD11B1 (0.44) | KMT2AKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL5534109 | 0.69 | ALDH1A1 (0.40) | KMT2AKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL6472239 | 0.68 | RXFP1 (0.43) | KMT2AALDH1A1HPGD | |
| SCHEMBL2141684 | 0.67 | KMT2A (0.38) | KMT2AKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL5527145 | 0.67 | ACHE (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | KMT2A 693/4885KDM4E 1190/4885ALDH1A1 2036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.